US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
AAPL
$333.69
▲+1.02%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
AAPL
$333.69
▲+1.02%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
BridgeBio Pharma, Inc. - Common Stock
(NQ:
BBIO
)
67.25
+0.34 (+0.51%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about BridgeBio Pharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
September 23, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 18, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
September 09, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
September 02, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Participate in September Investor Conferences
September 01, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
August 31, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
August 30, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
August 26, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
August 24, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
August 14, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
August 13, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 11, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
August 10, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
August 03, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
July 22, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
July 02, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
July 01, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
June 28, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 23, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
June 22, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
May 27, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
May 12, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
May 11, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 08, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
May 07, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Participate in May and June Investor Conferences
May 06, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
May 06, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
May 05, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
May 04, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
